Editas Medicine (EDIT) – Litigation
-
Editas Medicine (EDIT) Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference
-
Editas Medicine (EDIT) Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR Interference
-
-
-
-
Back to EDIT Stock Lookup